NeuroPace expects minimal impact of tariffs on its operations and financial results
Source: SeekingAlpha
2025-04-14 16:21:17 ET
More on NeuroPace
- NeuroPace, Inc. (NPCE) Q4 2024 Earnings Call Transcript
- NeuroPace, Inc. 2024 Q4 - Results - Earnings Call Presentation
- Stryker, Boston Scientific down as new tariffs impact medtech industry
- NeuroPace refocuses product portfolio; reaffirms 2025 revenue guidance
- Seeking Alpha’s Quant Rating on NeuroPace
Read the full article on Seeking Alpha
For further details see:
NeuroPace expects minimal impact of tariffs on its operations and financial results
Neuropace Inc.
NASDAQ: NPCE
NPCE Trading
0.35% G/L:
$14.35 Last:
15,675 Volume:
$14.30 Open:
NPCE Latest News
March 03, 2026 04:05:00 pm
NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook
NPCE Stock Data
$508,942,176
26,479,649
0.24%
22
N/A
Medical Equipment & Supplies
Healthcare
US
Mountain View
